When people are first infected with HIV, temporary treatment with antiretroviral drugs (cART) for 24 weeks can delay the need to restart treatment during chronic HIV infection, says a new study published in this week's PLoS Medicine.
These findings are important as currently, treatment for people with HIV is often deferred until the CD4 count falls below a certain level (350) or is based on clinical symptoms.
In a study led by Marlous Grijsen from the Academic Medical Center, University of Amsterdam in the Netherlands, 168 patients with primary HIV infection were randomized to receive no treatment, 24 weeks of cART, or 60 weeks of cART. They found that the average viral setpoint (the stable point that is reached in the amount of virus in the blood after the immune system begins to make antibodies to HIV) was lower in the patients who received early cART than in those who had no treatment.
Furthermore, on average, patients who received no treatment started long term treatment with cART before those who received early temporary treatment0.7 years after randomization whereas those receiving 24 and 60-week treatment restarted cART after 3 years and 1.8 years, respectively.
The authors say: "This randomized study demonstrates a clear clinical benefit of temporary cART initiated during [primary HIV Infection]. Early cART transiently lowered the viral set point and deferred the need for restart of cART during chronic HIV infection."
They continue: "Although extended follow-up studies are needed to evaluate the long-term benefits of such early treatment, starting cART when the patient is ready to do so seems the most reasonable advice for patients with [primary HIV Infection]."